AdvaMedDx and AdvaMedDx Member Companies Make Commitments to Combat AMR
WASHINGTON, D.C. – In partnership with the Centers for Disease Control and Prevention (CDC) through the Antimicrobial Resistance (AMR) Challenge, AdvaMedDx and several AdvaMedDx member companies made public commitments to bolster efforts to combat the global prevalence of AMR. The CDC will be accepting commitments over the course of the next year.
“AdvaMedDx member companies work hard every day to discover, develop and deliver innovative diagnostic solutions for early detection and surveillance of resistant germs,” said Susan Van Meter, Executive Director of AdvaMedDx. “We are proud to showcase their achievements and we are dedicated to ensuring the global policy landscape supports their efforts. In the fight against AMR, everyone has a part to play, and the diagnostics community looks forward to helping drive progress through the CDC’s AMR Challenge.”
In its AMR Challenge commitment, AdvaMedDx promised to advocate for policies that incentivize and support robust antibiotic stewardship programs informed by diagnostic data; educate provider and professional organizations to encourage the appropriate use of diagnostics in antibiotic stewardship programs; and raise awareness of AMR for domestic and international lawmakers and other relevant stakeholders.
AdvaMedDx member companies also making early AMR Challenge commitments include BD, bioMérieux, Cepheid and Roche Diagnostics.
The AMR Challenge is a multi-year initiative spearheaded by the CDC to encourage cross-sector collaboration to address the threat of AMR to public health. The Challenge focuses on five commitment areas: tracking and data; infection prevention and control; antibiotic use; environment and sanitation; and vaccines, therapeutics, and diagnostics.
View more information about AdvaMedDx’s commitment and the AMR Challenge here.